Benitez-Majano, S; Fowler, H; Maringe, C; Di Girolamo, C; Rachet, B (2016) Deriving stage at diagnosis from multiple population-based sources: colorectal and lung cancer in England. British journal of cancer, 115 (3). pp. 391-400. ISSN 0007-0920 DOI: https://doi.org/10.1038/bjc.2016.177

Downloaded from: http://researchonline.lshtm.ac.uk/2551481/

DOI: 10.1038/bjc.2016.177

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Supplementary Web-Appendix

Contents
Web-Appendix Figure 1. Deriving T component of TNM stage for colorectal cancer, England, 2008-2012....................... 2
Web-Appendix Figure 2. Deriving N component of TNM stage for colorectal cancer, England, 2008-2012......................... 3
Web-Appendix Figure 3. Deriving M component of TNM stage for colorectal cancer, England, 2008-2012......................... 4
Web-Appendix Figure 4. Deriving TNM stage for lung cancer using the restrictive strategy, England, 2008-2012............. 5
Web-Appendix Figure 5. Deriving TNM stage for lung cancer using the non-restrictive strategy, England, 2008-2012.... 6
Web-Appendix Figure 6. Deriving T component of TNM stage for lung cancer, England, 2008-2012.............................. 7
Web-Appendix Figure 7. Deriving N component of TNM stage for lung cancer, England, 2008-2012............................ 8
Web-Appendix Figure 8. Deriving M component of TNM stage for lung cancer, England, 2008-2012............................. 9
Web-Appendix Figure 9. Age standardised net survival by TNM stage, England 2008-2012 ............................................. 10
Notes:................................................................................................................................................................................. 10
Web-Appendix Figure 1. Deriving T component of TNM stage for colorectal cancer, England, 2008-2012.

Initial count: 163,915 (100%)

T

-\[
\text{NBCCCAP } pT = 4
\]

Yes \( \rightarrow T = 4 \)

-\[
\text{Serosa involved or perforation +}
\]

Yes \( \rightarrow T = 4 \)

-\[
\text{NBCCCAP } pT = \#
\]

Yes \( \rightarrow T = \text{NBCCCAP } pT \text{ (1-3)} \)

No

-\[
\text{CAS } pT = \#
\]

Yes \( \rightarrow T = \text{CAS } pT \text{ (1-4)} \)

No

-\[
\text{NBCCCAP } cT = \#
\]

Yes \( \rightarrow T = \text{NBCCCAP } cT \text{ (1-4)} \)

No

-\[
\text{NBCCCAP MRI } cT +
\]

Yes \( \rightarrow T = \text{NBCCCAP MRI } cT \text{ (1-4)} \)

No

-\[
\text{CAS } cT = \#
\]

Yes \( \rightarrow T = \text{CAS } cT \text{ (1-4)} \)

No

-\[
\text{CAS } IT = \#
\]

Yes \( \rightarrow T = \text{CAS } IT \text{ (1-4)} \)

No

T missing (1)
Web-Appendix Figure 2. Deriving N component of TNM stage for colorectal cancer, England, 2008-2012.
Web-Appendix Figure 3. Deriving M component of TNM stage for colorectal cancer, England, 2008-2012.
Web-Appendix Figure 4. Deriving TNM stage for lung cancer using the restrictive strategy, England, 2008-2012.
Web-Appendix Figure 5. Deriving TNM stage for lung cancer using the non-restrictive strategy, England, 2008-2012.
Web-Appendix Figure 6. Deriving T component of TNM stage for lung cancer, England, 2008-2012.

Initial count: 168,158 (100%)

1. **LUCADA pT ≠**
   - Yes: $T = \text{LUCADA pT (1-4)}$ [15,427 (9.2%)]
   - No:
     - **CAS pT ≠**
       - Yes: $T = \text{CAS pT (1-4)}$ [5,970 (3.6%)]
       - No:
         - **LUCADA cT ≠**
           - Yes: $T = \text{LUCADA cT (1-4)}$ [89,265 (53.1%)]
           - No:
             - **CAS cT ≠**
               - Yes: $T = \text{CAS cT (1-4)}$ [1,217 (0.7%)]
               - No:
                 - **CAS iT ≠**
                   - Yes: $T = \text{CAS iT (1-4)}$ [11,437 (6.8%)]
                   - No: T missing (,)

2. **T missing (,)**
   - [44,642 (26.7%)]
Web-Appendix Figure 7. Deriving N component of TNM stage for lung cancer, England, 2008-2012.

Initial count: 168,156 (100%)

- **LUCADA pN ≠**
  - Yes: N = LUCADA pN (1-3)
    - 15,177 (9.0%)
  - No:
    - **CAS pN pN ≥ 1**
      - Yes: N = CAS pN (1-3)
        - 3,827 (2.3%)
      - No:
        - **CAS positive nodes**
          - Yes: N > 0
            - 841 (0.5%)
          - No:
            - **CAS pN ≠**
              - Yes: N = CAS pN (0)
                - 3,087 (1.9%)
              - No:
                - **LUCADA cN ≠**
                  - Yes: N = LUCADA cN (1-3)
                    - 88,336 (52.9%)
                  - No:
                    - **CAS cN ≠**
                      - Yes: N = CAS cN (1-3)
                        - 1,274 (0.8%)
                      - No:
                        - **CAS IN ≠**
                          - Yes: N = CAS IN (1-3)
                            - 11,349 (6.7%)
                          - No: N missing (.)
                            - 44,267 (26.3%)
Web-Appendix Figure 8. Deriving M component of TNM stage for lung cancer, England, 2008-2012.
Web-Appendix Figure 9. Age standardised net survival by TNM stage, England 2008-2012

Notes:
T: Tumour component of TNM stage
NBOCAP: National Bowel Cancer Project
pT: Pathological T
%: Percent
+: Positive
≠: Not equal to
.: Missing
CAS: Cancer Analysis System
cT: Clinical T
MRI: Magnetic Resonance Imaging
iT: Integrated T
N: Lymph nodes component of TNM stage
pN: Pathological N
≥: Greater than or equal to
cN: Clinical N
iN: Integrated N
M: Distant Metastases component of TNM stage
cM: Clinical M
CT: Computerised Tomography scan
pM: Pathological M
iM: Integrated M
pStage: Pathological TNM Stage
cStage: Clinical TNM Stage
iStage: Integrated TNM Stage
LUCADA: Lung Cancer Audit Database